BridgeBio Oncology Therapeutics Inc.
Status: Publicly traded
Direct answer
BridgeBio Oncology Therapeutics Inc. is publicly traded on NASDAQ under the ticker BBOT.
BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical firm dedicated to pioneering advanced small molecule treatments. These therapies are aimed at combating malignancies driven by RAS and PI3Kα, both frequently encountered oncogenes in human cancers. Initially established as an offshoot of BridgeBio Pharma, the company concentrates on precision oncology. Its developmental pipeline features...
Can you invest in BridgeBio Oncology Therapeutics Inc.?
Yes. BridgeBio Oncology Therapeutics Inc. is publicly traded on NASDAQ under the ticker BBOT.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for BridgeBio Oncology Therapeutics Inc.
Detailed equity research is provided by MarketSnap.